VICTOZA (liraglutide), antidiabetic

DIABETOLOGY - New indication
Opinions on drugs - Posted on Aug 24 2015 - Updated on Aug 24 2015

Reason for request

Extension of indication

No clinical benefit demonstrated in the management of patients with type 2 diabetes in triple therapy

No role in the therapeutic strategy in dual therapy


  • VICTOZA now has Marketing Authorisation in the treatment of type 2 (adult-onset) diabetes for the achievement of glycaemic control combined with basal insulin, with or without an oral antidiabetic, when these, combined with diet and exercise, do not provide adequate glycaemic control.
  • Its efficacy has been demonstrated in placebo controlled study in triple therapy with basal insulin and metformin.
  • Its use combined with basal insulin and metformin is restricted to patients with type 2 diabetes inadequately controlled by the combination of these two medicinal products and who are intolerant to or have a contraindication to the use of a sulfonylurea, or in whom triple therapy with insulin/metformin/sulfonylurea has failed.

Clinical Benefit




Clinical Added Value

no clinical added value


Not applicable

Therapeutic use



Contact Us

Évaluation des médicaments